Mitochondrial antioxidant MitoQ reduces Alzheimer's pathology in symptomatic mice
Oral treatment improved behavioral deficits, suppressed amyloid plaques, lowered neuroinflammation, and restored mitochondrial quality control in mice with established disease.
In a study of four-month-old 5XFAD mice, researchers evaluated the effects of oral treatment with the mitochondria-targeted antioxidant MitoQ10. The mice received the compound for four months and underwent testing at eight months of age. MitoQ improved novelty-related exploration and reduced hyper-locomotor activity. It broadly suppressed amyloid pathology across the cortex, hippocampus, thalamus, and amygdala, reducing pan-Aβ, oligomeric Aβ species, fibrillar plaques, and mature deposits. MitoQ also reduced pathological pTau622, attenuated astrocyte and microglial reactivation, and preserved neuronal integrity. Furthermore, the intervention increased PDH-positive mitochondrial particle area, lowered oxidative DNA damage, and normalized mitophagy-associated quality-control markers in animals with established pathology.
Why it matters
Mitochondrial dysfunction and oxidative stress are core hallmarks of aging that exacerbate neurodegeneration. Restoring mitochondrial redox balance offers a potential path to target amyloid burden, tau pathology, and neuroinflammation concurrently.
Caveats
The findings are limited to an animal model of Alzheimer's disease. Direct clinical studies are still required to assess the safety and efficacy of MitoQ in human patients with the condition.
- Mitoq
- Disabled macroautophagy
- Genomic instability
- Mitochondrial dysfunction
- Mitophagy
- Oxidative stress and ROS signalling
- Alzheimer's disease
- Amyloid pathology
- Oxidative DNA damage
- pTau622
- Mus musculus
The paper
Repurposing MitoQ10 as a Therapeutic for Established Alzheimer's Disease Pathology
Kumar M, Ray S, Sil S
Aging and Disease · 22 Sep 2026